Exaire, J E <br/><br/>
Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes.  [electronic resource] 

 -  Journal of thrombosis and haemostasis : JTH  Jan 2004 
 - 7-9 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1538-7933 
<br/><br/><label>Standard No.: </label>10.1111/j.1538-7836.2004.00559.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abciximab<br/>Angioplasty, Balloon, Coronary--methods<br/>Antibodies, Monoclonal--adverse effects<br/>Cost-Benefit Analysis<br/>Humans<br/>Immunoglobulin Fab Fragments--adverse effects<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Platelet Glycoprotein GPIIb-IIIa Complex--antagonists & inhibitors<br/>Safety